1Nomura H, Sou S, Tanimoto H, et al. Short-term interferonalfa therapy for acute hepatitis C: a randomized controlled trial[J]. Hepatology, 2004,39(5): 1213-1219.
2Kamal SM, Moustefa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial[J]. Hepatology, 2006,43(5): 923-931.
3Poynard T, McHutchison J, Goodman Z, et al. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? [J]. Hepatology, 2000,31(1): 211-218.
4Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? [J]. J Gastroenterol Hepatol,2000,15 (Suppl): E141-E151.
5Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels [J]. Gastroenterology, 2005,128 (5): 1531-1532.
7Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med, 2004, 140(5): 346-355.
8Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks HCV genotype 2 or 3 [J]. N Engl J Med, 2005,352(25): 2609-2617.
9Dalgard O, Bjoro K, Helium KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study [J]. Hepatology, 2004,40 (6): 1260-1265.
10Shiffmann ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[J]. Gastroenterology, 2004, 126(4): 1015-1023.
